On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Makoto Tahara

ResearcherPublications, citations & collaboration network

Makoto Tahara is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Makoto Tahara have?

ScholarIQindexed works

Makoto Tahara has 606 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Makoto Tahara have?

ScholarIQcitation count

Makoto Tahara has 32,018 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Makoto Tahara?

ScholarIQh-index

Makoto Tahara has an h-index of 64 in OpenAlex.

What is the i10-index of Makoto Tahara?

ScholarIQi10-index

Makoto Tahara has an i10-index of 259 in OpenAlex.

What is the ORCID of Makoto Tahara?

ScholarIQorcid

The ORCID for Makoto Tahara is on the source record.

What is the OpenAlex record for Makoto Tahara?

ScholarIQopenalex

The OpenAlex for Makoto Tahara is on the source record.

What are the most-cited papers on Makoto Tahara?

ScholarIQmost cited works
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, J. Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
New England Journal of Medicine. 20165,125 CitationsOPEN ACCESS
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett Hughes, Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey‐Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gümüşçü, Jonathan D. Cheng, Fan Jin, Danny Rischin, Guillermo Lerzo, Marcelo Tatangelo, Mirta Varela, Juan José Zarbá, Michael Boyer, Hui Gan, Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi
The Lancet. 20193,274 CitationsOPEN ACCESS
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung‐Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begoña de las Heras, Junming Zhu, Steven I. Sherman
New England Journal of Medicine. 20152,094 CitationsOPEN ACCESS
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian, Jordan Berlin, Noah Federman, Leo Mascarenhas, Birgit Geoerger, Afshin Dowlati, Alberto S. Pappo, Stefan Bielack, François Doz, Ray McDermott, Jyoti D. Patel, Russell J. Schilder, Makoto Tahara, Stefan M. Pfister, Olaf Witt, Marc Ladanyi, Erin R. Rudzinski, Shivani Nanda, Barrett H. Childs, Theodore W. Laetsch, David M. Hyman, Alexander Drilon
The Lancet Oncology. 20201,009 CitationsOPEN ACCESS
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert
Journal of Clinical Oncology. 2016863 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account